Rational immunotherapy in the combination treatment of community-acquired pneumonia

Rational immunotherapy in the combination treatment of community-acquired pneumonia

The article analyzes the immunomodulatory therapy as part of pathogenetic treatment of community-acquired pneumonia. Immunological monitoring of patients with severe community-acquired pneumonia demonstrated a disbalance of natural resistance factors, cellular component of immune system and humoral...

Full description

Bibliographic Details
Main Authors:	G. A. Mavzyutova, L. R. Mukhamadieva, R. M. Fazlyeva, G. K. Mirsaeva, E. B. Tyurina
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2015-12-01
Series:	Медицинский совет
Subjects:	внебольничная пневмония иммунокоррекция иммунопатогенез азоксимера бромид (полиоксидоний) community-acquired pneumonia immunotherapy immunopathogenesis azoximer bromide (polyoxidonium)
Online Access:	https://www.med-sovet.pro/jour/article/view/410

Similar Items

Enhancement of the Yersinia pestis EV NIIEG Vaccine Srain Immunogenic and Protective Activity under Cultivation with Azoxymer Bromide (Polyoxidonium)
by: T. N. Shchukovskaya, et al.
Published: (2022-01-01)

ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
by: V. F. Uchaikin
Published: (2017-09-01)

Frequent respiratory viral infections in children. What should be done?
by: G. N. Nikiforova, et al.
Published: (2016-12-01)

СLINICAL AND IMMUNOLOGICAL EFFICIENCY OF IMUNOFAN AND POLYOXIDONIUM IN COMBINED THERAPY OF COMMUNITY-ACQUIRED PNEUMONIA
by: L. R. Mukhamadieva, et al.
Published: (2014-07-01)

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
by: Sergey V Efimov, et al.
Published: (2021-03-01)

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
by: Sergey V Efimov, et al.
Published: (2021-06-01)

Use of azoximer bromide for treatment of children's inflammatory infections of respiratory system: a meta-analysis of controlled clinical studies
by: A. V. Karaulov, et al.
Published: (2019-12-01)

Role of immunocorrection therapy in comprehensive treatment of patients with inflammatory diseases of female genital organs
by: Natalia A. Shchukina, et al.
Published: (2020-05-01)

Azoximer bromide-modulated immune response in aerobic vaginitis
by: G. B. Dikke, et al.
Published: (2022-01-01)

CLINICAL APPROACH TO IMMUNOCORRECTION IN COMMUNITY-ACQUIRED PNEUMONIA
by: G. A. Mavzyutova, et al.
Published: (2017-07-01)

Clinical and Etiological Features of Community-acquired Pneumonia in Children in Vladivostok
by: L. G. Erokhina, et al.
Published: (2015-12-01)

Azithromycin in the Treatment of Community-acquired Pneumonia in Children
by: N. I. Zryachkin, et al.
Published: (2016-04-01)

Features of the clinical presentation and course of community-acquired pneumonia against the background of type 2 diabetes mellitus
by: A. A. Zaytseva, et al.
Published: (2022-07-01)

Community-acquired pneumonia as a common acute infectious disease of the respiratory system
by: A. A. Wiesel, et al.
Published: (2014-12-01)

Community-acquired pneumonia in HIV patients
by: I. B. Viktorova, et al.
Published: (2021-05-01)

Potential of azoximere bromide for treatment of patients with acute inflammatory and infectious upper respiratory diseases
by: Valery M. Svistushkin, et al.
Published: (2023-12-01)

Community-acquired pneumonia in children: antibacterial therapy
by: Y. L. Mizernitsky
Published: (2013-12-01)

Management of myeloperoxidase activity of leukocytes in those suffering from community acquired pneumonia with the help of low-intesive lazer radiation of blood
by: N. M. Burduli, et al.
Published: (2016-04-01)

Efficacy of azoximer bromide in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia
by: S. K. Zyryanov, et al.
Published: (2021-12-01)

Problems of differential diagnosis of community-acquired pneumoni
by: O. V. Fesenko, et al.
Published: (2015-12-01)

The Effectiveness of Immunomodulatory Therapy of Community-acquired Pneumonia in Frequently ill Children
by: T. G. Malanicheva, et al.
Published: (2018-12-01)

Evaluation of the Preventive Efficacy and Safety of Azoximer Bromide in Healthcare Workers in Contact with Patients Hospitalized for COVID-19
by: K V Kasyanenko, et al.
Published: (2022-03-01)

Complicated community-acquired pneumonia in a child caused by multidrug-resistant Streptococcus pneumoniae: features of disease course, error analysis
by: R. N. Mamleev
Published: (2017-11-01)

ADJUNCTIVE THERAPY OF COMMUNITY-ACKUIRED PNEUMONIA: NECESSITY AND SUFFICIENCY
by: L. V. Savchenkova, et al.
Published: (2016-12-01)

Evaluation of relationships between indicators of the oxidative-antioxidative system and force of respiratory muscles in the case of community-acquired pneumonia
by: E. P. Kalinina, et al.
Published: (2020-04-01)

Diagnostics and complex treatment of inveterate apical periodontitis in acute condition
Published: (2020-04-01)

Local cytokine profile and cytological status in children with community-acquired pneumonia arising on the background of the reduced resistance of the organism
by: T. G. Malanicheva, et al.
Published: (2017-11-01)

Use of immunomodulatory therapy as part of comprehensive treatment of non-severe community-acquired pneumonia and its long-term results
by: Mikhail P Kostinov, et al.
Published: (2023-08-01)

Central Hemodynamics and Extravascular Lung Water Index in Varying Degrees of Community-Acquired Pneumonia
by: S. N. Avdeykin, et al.
Published: (2015-09-01)

Diagnostic and pharmacological approaches to the management of patients with community-acquired pneumonia in outpatient setting
by: A. A. Zaitsev
Published: (2014-12-01)

The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia
by: M. P. Kostinov, et al.
Published: (2021-05-01)

Problems of assessing the severity of the state of elderly patients with community-acquired pneumonia caused by Klebsiella pneumoniae
by: V. I. Sakharov, et al.
Published: (2020-12-01)

Development of a model for the differential diagnosis of community-acquired bacterial pneumonia and viral lung injury in hospitalized adult patients
by: O. A. Kupriushina, et al.
Published: (2024-02-01)

Community-acquired pneumonia in children – problems and solutions
by: V. K. Tatochenko
Published: (2021-03-01)

EFFICIENCY OF TRANSPULMONARY THERMODILUTION IN THE OPTIMIZATION OF INTENSIVE TREATMENT IN PATIENTS WITH SEVERE NOSOCOMIAL PNEUMONIA
by: S. N. Avdeykin, et al.
Published: (2015-05-01)

Prediction of lethal outcomes in COVID-19 cases based on the results chest computed tomography
by: S. P. Morozov, et al.
Published: (2020-07-01)

Evaluation of the functional state of the small intestine of patients using antibiotics for treatment of out-hospital pneumonia
by: Y. M. Vahrushev, et al.
Published: (2015-10-01)

Persistent pathogens as risk factors of community-acquired pneumonia and acute bronchitis in children
by: O. V. Zhukova, et al.
Published: (2016-07-01)

EFFICIENCY OF ANTI-INFLAMMATORY AND IMMUNOMODULATORY THERAPY OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN WITH RECURRENT RESPIRATORY DISEASES
by: T. G. Malanicheva, et al.
Published: (2018-11-01)

INFLAMMATION ROLE IN FORMATION OF EARLY DISTURBANCES OF A FUNCTIONAL CONDITION OF A LIVER AT COMMUNITY — ACQUIRED PNEUMONIA (LITERATURE REVIEW)
by: A. Yu. Gorbunov, et al.
Published: (2018-10-01)